

LILLY'S RESPONSE TO COVID-19



Lilly's purpose – to make life better – has never been more important.

— David A. Ricks, Chairman and Chief Executive Officer

Lilly is bringing the full force of our scientific and medical expertise to attack the coronavirus pandemic around the world. We're focused on ensuring a reliable supply of medicines, keeping our employees safe and pushing scientific efforts to **defeat this virus**. We're also committed to supporting our communities, including reducing strain on the medical system.

Supplying Medicines



Supplying medication to nearly **40 million people** across 125 countries



Operating all **14 Lilly manufacturing sites** during the pandemic



Keeping the **flow of medicines** and supplies moving across borders, despite challenges



Keeping Our Employees Safe

- More than **25,000 employees** working from home
- For employees who must be in our facilities to make and supply medicines, numerous steps were taken to keep them safe and ensure social distancing
- In Indiana, Lilly joined with Gov. Eric Holcomb and 7 other partners to launch the **#INThisTogether** community awareness campaign

Supporting Our Communities

- Introduced the Lilly Insulin Value Program, which caps monthly patient **out-of-pocket at \$35/Rx***
- **Reduced strain** on the medical system
 - Donated PPE around the world, including equipment produced by Lilly employees
 - Enabled employee medical volunteers
 - Paused new clinical trial starts and enrollment for most programs
 - Suspended in-person customer visits
- Thousands of employees have volunteered, including more than 1,200 at our testing site, live in Indianapolis and virtually from California, Colorado, New Jersey, New York and elsewhere
- Around the world, Lilly employees and the Lilly Foundation have given **more than \$1.65 million in donations** to date in response to COVID-19
- Joined a cross-industry collaboration of 17 life sciences companies and the Bill & Melinda Gates Foundation

* Terms, conditions, and limitations apply. Not available to those patients with government insurance such as Medicaid, Medicare, Medicare Part D, TRICARE®/CHAMPUS, Medigap, DoD, or any State Patient or Pharmaceutical Assistance Program.

May 2020 Approved for External Use ©2020, Eli Lilly and Company. ALL RIGHTS RESERVED.

**“We are moving at top speed to
create a potential treatment
to help patients.”**


— **Daniel Skovronsky, M.D., Ph.D.**

Chief Scientific Officer and President, Lilly Research Laboratories


Attacking the Pandemic



Confronting this pandemic with everything we can, through R&D in Lilly's own labs and partnerships with other companies and the government



Working to develop new potential therapies as well as testing existing medicines with potential to address COVID-19



Repurposed labs at Lilly Corporate Center to conduct diagnostic testing in Indiana for COVID-19



Established and opened **drive-through COVID-19 testing** site in less than 3 weeks; Lilly is the only pharmaceutical company in the U.S. to do this



Tested **over 60,000 samples**, a combination of samples from drive-through and Indiana State Department of Health's testing efforts



Lilly does not accept money from government agencies, hospitals, insurance companies or patients for conducting or analyzing tests

Find out more at [Lilly.com](https://www.lilly.com)

This document contains forward-looking statements regarding Lilly's efforts in regard to the novel coronavirus. These statements are based on management's current expectations, but actual results may differ materially. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

May 2020 Approved for External Use ©2020, Eli Lilly and Company. ALL RIGHTS RESERVED.